Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV

Summary Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes in cytokine levels, innate immune cell subsets, and gene expression. Integrative statistical analyses with cross-validation identified a signature of 5 early innate markers correlating with antibody titers on day 28 and beyond. Among those, IP-10 on day 3 and MFI of CXCR6 on NK cells on day 1 were independent correlates. Consistently, we found an early gene expression signature linked to IP-10. This comprehensive characterization of early innate immune responses to the rVSV-ZEBOV vaccine in humans revealed immune signatures linked to IP-10. These results suggest correlates of vaccine-induced antibody induction and provide a rationale to explore strategies for augmenting the effectiveness of vaccines through manipulation of IP-10.

[1]  A. Telenti,et al.  Critical role for the chemokine receptor CXCR 6 in NK cell – mediated antigen-specific memory of haptens and viruses , 2010 .

[2]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[3]  G. Barber,et al.  Cutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective Immunity , 2017, The Journal of Immunology.

[4]  M. Altfeld,et al.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.

[5]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[6]  Tae Woo Kim,et al.  Modification of dendritic cells with interferon‐γ‐inducible protein‐10 gene to enhance vaccine potency , 2009, The journal of gene medicine.

[7]  H. Young,et al.  Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection , 2004, The Journal of experimental medicine.

[8]  Boris P. Hejblum,et al.  Group and sparse group partial least square approaches applied in genomics context , 2015, Bioinform..

[9]  Mark M. Davis,et al.  Apoptosis and other immune biomarkers predict influenza vaccine responsiveness , 2014, Molecular Systems Biology.

[10]  Anne-Laure Boulesteix,et al.  Partial least squares: a versatile tool for the analysis of high-dimensional genomic data , 2006, Briefings Bioinform..

[11]  Philippe Besse,et al.  Statistical Applications in Genetics and Molecular Biology A Sparse PLS for Variable Selection when Integrating Omics Data , 2011 .

[12]  Sandra Romero-Steiner,et al.  Molecular signatures of antibody responses derived from a systems biology study of five human vaccines , 2022 .

[13]  John-Arne Røttingen,et al.  Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.

[14]  Heinz Feldmann,et al.  Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus , 2009, Journal of Virology.

[15]  U. V. Andrian,et al.  Natural killer cell memory , 2011, Nature Immunology.

[16]  J. Strong,et al.  VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain , 2015, Science.

[17]  Shuzhao Li,et al.  Systems vaccinology: Probing humanity’s diverse immune systems with vaccines , 2014, Proceedings of the National Academy of Sciences.

[18]  F. Finkelman,et al.  CD40-mediated stimulation contributes to lymphocyte proliferation, antibody production, eosinophilia, and mastocytosis during an in vivo type 2 response, but is not required for T cell IL-4 production. , 1996, Journal of immunology.

[19]  B. Murphy,et al.  Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus , 2007, Journal of Virology.

[20]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[21]  Steven J M Jones,et al.  Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates , 2008, PLoS pathogens.

[22]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[23]  W. Kalina,et al.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. , 2007, The Journal of infectious diseases.

[24]  Kim-Anh Lê Cao,et al.  A novel approach for biomarker selection and the integration of repeated measures experiments from two assays , 2012, BMC Bioinformatics.

[25]  Y. Benjamini,et al.  On the Adaptive Control of the False Discovery Rate in Multiple Testing With Independent Statistics , 2000 .

[26]  X. Qiu,et al.  Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses , 2009, PloS one.

[27]  D. Barouch,et al.  Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys , 2012, Journal of Virology.

[28]  F. Ramsdell,et al.  Recombinant CD40 ligand exerts potent biologic effects on T cells. , 1994, Journal of immunology.

[29]  S. Dow,et al.  Suppression of Vaccine Immunity by Inflammatory Monocytes , 2012, The Journal of Immunology.

[30]  L. Fernando,et al.  Effective Post-Exposure Treatment of Ebola Infection , 2007, PLoS pathogens.

[31]  M. Dziejman,et al.  IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.

[32]  J. Christensen,et al.  CXCL10 Is the Key Ligand for CXCR3 on CD8+ Effector T Cells Involved in Immune Surveillance of the Lymphocytic Choriomeningitis Virus-Infected Central Nervous System1 , 2006, The Journal of Immunology.

[33]  Mark M. Davis,et al.  Apoptosis and other immune biomarkers predict influenza vaccine responsiveness , 2013, Molecular systems biology.

[34]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[35]  Eva K. Lee,et al.  Systems Biology of Seasonal Influenza Vaccination in Humans , 2011, Nature Immunology.

[36]  Robert Tibshirani,et al.  Spectral Regularization Algorithms for Learning Large Incomplete Matrices , 2010, J. Mach. Learn. Res..

[37]  T. Kita,et al.  Molecular Cloning of a Novel Scavenger Receptor for Oxidized Low Density Lipoprotein, SR-PSOX, on Macrophages* , 2000, The Journal of Biological Chemistry.

[38]  X. Qiu,et al.  Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates , 2012, Science Translational Medicine.

[39]  U. Reimer,et al.  Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). , 2013, The Journal of infectious diseases.

[40]  D. Sansom,et al.  What's the difference between CD80 and CD86? , 2003, Trends in immunology.

[41]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[42]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[43]  Tae Woo Kim,et al.  Enhancement of DNA vaccine potency by antigen linkage to IFN‐γ‐inducible protein‐10 , 2011, International journal of cancer.